Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.73 |
| ▸ | GSR | P00390 | 2/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL6014744 | 1.00 | PTGS1 (0.73) | PTGS1SLC7A11GSRCPB2ENPEP | |
| Cysteine SCHEMBL5664976 | 0.95 | PTGS1 (0.80) | PTGS1SLC7A11GSRCPB2ENPEP | |
| Cysteine SCHEMBL5664971 | 0.95 | PTGS1 (0.80) | PTGS1SLC7A11GSRCPB2ENPEP | |
| Cysteine SCHEMBL1819440 | 0.91 | PTGS1 (0.89) | PTGS1SLC7A11GSRENPEPGRIK1 | |
| Cysteine SCHEMBL27530294 | 0.91 | — | — | |
| Cysteine SCHEMBL1819437 | 0.91 | PTGS1 (0.89) | PTGS1SLC7A11GSRENPEPGRIK1 | |
| Cysteine SCHEMBL15417993 | 0.88 | PTGS1 (0.84) | PTGS1SLC7A11GSRCPB2ENPEP | |
| Cysteine SCHEMBL3420204 | 0.88 | PTGS1 (0.84) | PTGS1SLC7A11GSRCPB2ENPEP | |
| Cysteine SCHEMBL15418989 | 0.88 | PTGS1 (0.84) | PTGS1SLC7A11GSRCPB2ENPEP | |
| Cysteine SCHEMBL5831493 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081472-B2 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K. U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-07-25 | — | — | US | claimed |
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-03-18 | — | — | US | claimed |
| EP-1343758-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2003-09-17 | — | — | EP | claimed |
| WO-2002038546-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-05-16 | — | — | WO | claimed |
| EP-0998946-A1 | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-05-10 | — | — | EP | claimed |
| WO-2000009169-A1 | NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-02-24 | — | — | WO | claimed |
| US-7081472-B2 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K. U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-03-18 | — | — | US | disclosed |
| EP-1343758-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002038546-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | IDO1, IDO2, CNR1 | PTGS1 1041/4885SLC7A11 2289/4885GSR 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.